News News and Resources

Phosphorex, a contract development and manufacturing organization (CDMO) focused on drug delivery, has named Jerry Williamson as its new Chief Executive Officer. Williamson brings more than 35 years of leadership experience across bioscience and diagnostics, including CEO roles at Sengenics,

Veranova, a global developer and manufacturer of specialty and complex active pharmaceutical ingredients (APIs), has successfully completed a routine cGMP surveillance inspection at its Devens, Massachusetts site. The inspection, conducted by the FDA New England District on July 31, 2025,

Avista Therapeutics, a pre-clinical-stage biotechnology company, has partnered with Forge Biologics, a manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, to develop AVST-101. The therapy targets X-linked retinoschisis (XLRS), a serious inherited retinal disease. Under the

WuXi Biologics has reported that its WuXiUP™ intensified perfusion culture process has reached a milestone with end-to-end, fully automated continuous drug substance production at pilot scale. The platform will be deployed across the company’s major GMP manufacturing sites to enhance

Pace® Life Sciences, a U.S.-based contract research, development, and manufacturing organisation (CRDMO) and FDA-registered GMP analytical testing laboratory, has reopened its 33,000 square foot facility in Salem, New Hampshire. The upgraded site now serves as a Centre of Excellence for

Bionova Scientific®, a biologics contract development and manufacturing organisation (CDMO) and subsidiary of Asahi Kasei, has opened a 10,000 square-foot plasmid DNA (pDNA) development and production facility in The Woodlands, Texas. The site is designed to supply research-grade pDNA to

AbbVie has announced a $195 million investment in its North Chicago, Illinois, manufacturing site to expand domestic active pharmaceutical ingredient (API) production. The expansion is part of AbbVie’s broader plan to invest more than $10 billion in the U.S., aiming

Cohance Lifesciences has revealed a strategic investment of USD 10 million to grow its cGMP bioconjugation capabilities at NJ Bio, its subsidiary based in Princeton, New Jersey. The expansion aligns with Cohance’s global strategy to strengthen its contract research, development

Quantum BioPharma Ltd. has entered into an agreement with a leading contract development and manufacturing organisation (CDMO) to produce an oral formulation of Lucid-MS, the company’s investigational treatment for multiple sclerosis (MS). The oral formulation will be used in a

Sanner has announced a change in leadership as part of its strategic move to strengthen its position as a contract development and manufacturing organisation (CDMO) for medical devices and advanced pharmaceutical drug delivery systems. The company confirmed that CEO Dr.